Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia - A randomized, double-blind, placebo-controlled study
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia - A randomized, double-blind, placebo-controlled study
复制标题
DOI：
10.1001/archpsyc.62.11.1196
复制
发表时间：
2005-11-01
影响因子：
--
通讯作者：
Tsai, GE
中科院分区：
文献类型：
--
作者：
Lane, HY;Chang, YC;Tsai, GE
背景：通过甘氨酸调节位点（D-丝氨酸、甘氨酸或 D-环丝氨酸）或通过甘氨酸转运蛋白 1（肌氨酸）增强 N-甲基-D-天冬氨酸 (NMDA) 功能的药物可改善稳定型慢性精神分裂症患者的症状。 目的：确定 NMDA-甘氨酸位点激动剂或甘氨酸转运蛋白-1 抑制剂是否具有更好的疗效以及 NMDA 受体增强剂是否有效对精神分裂症急性加重有有益作用。设计：随机、双盲、安慰剂对照试验。地点：台湾 2 个主要医疗中心的住院部。患者：65 名急性加重的精神分裂症住院患者。干预措施：用肌氨酸（2 g/d）、D-丝氨酸（2 g/d）或安慰剂和伴随最佳治疗治疗六周主要结果指标：阳性和阴性症状量表（PANSS）和阴性症状评估量表（SANS）（20 和 17 项）总分。 结果：肌氨酸组显示 PANSS 总分比安慰剂组 (P=.04) 和 D-丝氨酸组 (P=.04) 降低更多。
Context: Agents that enhance N-methyl-D-aspartate (NMDA) function through the glycine modulatory site (D-serine, glycine, or D-cycloserine) or through glycine transporter 1 (sarcosine) improve the symptoms of patients with stable chronic schizophrenia.Objective: To determine whether NMDA-glycine site agonists or glycine transporter-1 inhibitors have better efficacy and whether NMDA receptor-enhancing agents have beneficial effects for acute exacerbation of schizophrenia.Design: Randomized, double-blind, placebo-controlled trial.Setting: Inpatient units of 2 major medical centers in Taiwan.Patients: Sixty-five schizophrenic inpatients with acute exacerbation.Interventions: Six weeks of treatment with sarcosine (2 g/d), D-serine (2 g/d), or placebo and concomitant optimal risperidone therapy.Main Outcome Measures: Positive and Negative Syndrome Scale (PANSS) and Scale for the Assessment of Negative Symptoms (SANS) (20 and 17 items) total scores.Results: The sarcosine group revealed more reductions in PANSS total scores than the placebo (P=.04) and D-serine (P